JPWO2021234324A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021234324A5 JPWO2021234324A5 JP2022571216A JP2022571216A JPWO2021234324A5 JP WO2021234324 A5 JPWO2021234324 A5 JP WO2021234324A5 JP 2022571216 A JP2022571216 A JP 2022571216A JP 2022571216 A JP2022571216 A JP 2022571216A JP WO2021234324 A5 JPWO2021234324 A5 JP WO2021234324A5
- Authority
- JP
- Japan
- Prior art keywords
- oxazaphosphinane
- tetramethyl
- oxo
- ion
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 230000004112 neuroprotection Effects 0.000 claims description 28
- -1 methanesulfonate ion Chemical class 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000002265 prevention Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- RQHKZUBCUZVZEF-UHFFFAOYSA-N 1-phenyl-1-cyclohexanecarboxylic acid 2-(4-morpholinyl)ethyl ester Chemical compound C1CCCCC1(C=1C=CC=CC=1)C(=O)OCCN1CCOCC1 RQHKZUBCUZVZEF-UHFFFAOYSA-N 0.000 claims description 8
- JFABCGNHSUIPEL-UHFFFAOYSA-N 2-(3-chlorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound ClC=1C=C(C=CC=1)P1(OCC(NC1(C)C)(C)C)=O JFABCGNHSUIPEL-UHFFFAOYSA-N 0.000 claims description 8
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical compound C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 6
- 229940006460 bromide ion Drugs 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 4
- SRRUPDPTTGLICG-RBUKOAKNSA-N (1s,2r)-n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-pyrrolidin-1-ylcyclohexan-1-amine Chemical compound CN([C@@H]1[C@@H](CCCC1)N1CCCC1)CCC1=CC=C(Cl)C(Cl)=C1 SRRUPDPTTGLICG-RBUKOAKNSA-N 0.000 claims description 4
- BOTHKNZTGGXFEQ-UHFFFAOYSA-N 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1CCOC1(C=1C=CC=CC=1)C1=CC=CC=C1 BOTHKNZTGGXFEQ-UHFFFAOYSA-N 0.000 claims description 4
- UVSWWUWQVAQPJR-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCN(CCCC=2C=CC=CC=2)CC1 UVSWWUWQVAQPJR-UHFFFAOYSA-N 0.000 claims description 4
- TZZGTNZBLPCBIS-UHFFFAOYSA-N 1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC=2C(OC)=CC=CC=2N1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 TZZGTNZBLPCBIS-UHFFFAOYSA-N 0.000 claims description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 4
- VXPDJTOUDMXYGJ-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound ClC=1C=C(C=C(C=1)Cl)P1(OCC(NC1(C)C)(C)C)=O VXPDJTOUDMXYGJ-UHFFFAOYSA-N 0.000 claims description 4
- PRYUCEKGZMTVRK-UHFFFAOYSA-N 2-(4-chlorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound ClC1=CC=C(C=C1)P1(OCC(NC1(C)C)(C)C)=O PRYUCEKGZMTVRK-UHFFFAOYSA-N 0.000 claims description 4
- DWFOUYWIWBQGFK-UHFFFAOYSA-N 2-(4-fluorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound FC1=CC=C(C=C1)P1(OCC(NC1(C)C)(C)C)=O DWFOUYWIWBQGFK-UHFFFAOYSA-N 0.000 claims description 4
- QRLPFCPYPGPLQA-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-(3-nitrophenyl)-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound [N+](=O)([O-])C=1C=C(C=CC=1)P1(OCC(NC1(C)C)(C)C)=O QRLPFCPYPGPLQA-UHFFFAOYSA-N 0.000 claims description 4
- ZZUXYMPHBPDSHM-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-pyridin-2-yl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound N1=C(C=CC=C1)P1(OCC(NC1(C)C)(C)C)=O ZZUXYMPHBPDSHM-UHFFFAOYSA-N 0.000 claims description 4
- VXUGJNHPSMNENH-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-pyridin-3-yl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound N1=CC(=CC=C1)P1(OCC(NC1(C)C)(C)C)=O VXUGJNHPSMNENH-UHFFFAOYSA-N 0.000 claims description 4
- QMRXABLHOIKGLG-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-pyridin-4-yl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound N1=CC=C(C=C1)P1(OCC(NC1(C)C)(C)C)=O QMRXABLHOIKGLG-UHFFFAOYSA-N 0.000 claims description 4
- MOFNUJIYNQDGQJ-UHFFFAOYSA-N 3-(3,3,5,5-tetramethyl-2-oxo-1,4,2lambda5-oxazaphosphinan-2-yl)aniline Chemical compound NC=1C=C(C=CC=1)P1(OCC(NC1(C)C)(C)C)=O MOFNUJIYNQDGQJ-UHFFFAOYSA-N 0.000 claims description 4
- MWTSWMNORCYSBO-UHFFFAOYSA-N 4-(3,3,5,5-tetramethyl-2-oxo-1,4,2lambda5-oxazaphosphinan-2-yl)aniline Chemical compound NC1=CC=C(C=C1)P1(OCC(NC1(C)C)(C)C)=O MWTSWMNORCYSBO-UHFFFAOYSA-N 0.000 claims description 4
- HELCSESNNDZLFM-UHFFFAOYSA-N 4-iodo-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 HELCSESNNDZLFM-UHFFFAOYSA-N 0.000 claims description 4
- SYYDYQMUKFERQR-UHFFFAOYSA-N 6-[(4-benzylpiperazin-1-yl)methyl]-2,3-dimethoxyphenol Chemical compound OC1=C(OC)C(OC)=CC=C1CN1CCN(CC=2C=CC=CC=2)CC1 SYYDYQMUKFERQR-UHFFFAOYSA-N 0.000 claims description 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 102000010970 Connexin Human genes 0.000 claims description 4
- 108050001175 Connexin Proteins 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 4
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 4
- DGZZDMAMAYTPSV-UHFFFAOYSA-N N-phenylmethoxy-4-(3,3,5,5-tetramethyl-2-oxo-1,4,2lambda5-oxazaphosphinan-2-yl)benzamide Chemical compound C(C1=CC=CC=C1)ONC(=O)C1=CC=C(C=C1)P1(OCC(NC1(C)C)(C)C)=O DGZZDMAMAYTPSV-UHFFFAOYSA-N 0.000 claims description 4
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 4
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 claims description 4
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 claims description 4
- 229950008995 aducanumab Drugs 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 229960003530 donepezil Drugs 0.000 claims description 4
- 229960003720 enoxolone Drugs 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- VCZSWYIFCKGTJI-JLHYYAGUSA-N igmesine Chemical compound C1CC1CN(C)C(C=1C=CC=CC=1)(CC)C\C=C\C1=CC=CC=C1 VCZSWYIFCKGTJI-JLHYYAGUSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 229960003803 meclofenamic acid Drugs 0.000 claims description 4
- 229960001962 mefloquine Drugs 0.000 claims description 4
- LGQCVMYAEFTEFN-UHFFFAOYSA-N n-allylnormetazocine Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C)CC2 LGQCVMYAEFTEFN-UHFFFAOYSA-N 0.000 claims description 4
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 4
- RFPMGSKVEAUNMZ-UHFFFAOYSA-N pentylidene Chemical group [CH2+]CCC[CH-] RFPMGSKVEAUNMZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229960004136 rivastigmine Drugs 0.000 claims description 4
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002636 symptomatic treatment Methods 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 3
- 229940006461 iodide ion Drugs 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229940085991 phosphate ion Drugs 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000032859 Synucleinopathies Diseases 0.000 claims description 2
- 208000034799 Tauopathies Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 2
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000006727 cell loss Effects 0.000 claims description 2
- 230000003930 cognitive ability Effects 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000000971 hippocampal effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000008655 medium-term memory Effects 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000009223 neuronal apoptosis Effects 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 208000014670 posterior cortical atrophy Diseases 0.000 claims description 2
- 230000004224 protection Effects 0.000 claims description 2
- 230000006403 short-term memory Effects 0.000 claims description 2
- 230000006886 spatial memory Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- LYUGHJPXLXICHT-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound ClC1=C(C=CC=C1Cl)P1(OCC(NC1(C)C)(C)C)=O LYUGHJPXLXICHT-UHFFFAOYSA-N 0.000 claims 2
- ORMOQBLZUSJWOD-UHFFFAOYSA-N 2-(3-chlorophenyl)-3,3,4,5,5-pentamethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound CN1C(C)(C)COP(=O)(c2cccc(Cl)c2)C1(C)C ORMOQBLZUSJWOD-UHFFFAOYSA-N 0.000 claims 2
- WDEYHKLCVZHFMA-UHFFFAOYSA-N 2-(3-chlorophenyl)-3,3,5,5-tetramethyl-2-sulfanylidene-1,4,2lambda5-oxazaphosphinane Chemical compound ClC=1C=C(C=CC=1)P1(OCC(NC1(C)C)(C)C)=S WDEYHKLCVZHFMA-UHFFFAOYSA-N 0.000 claims 2
- BZPVRUBMPXSHSF-UHFFFAOYSA-N 2-(3-fluorophenyl)-3,3,5,5-tetramethyl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound FC=1C=C(C=CC=1)P1(OCC(NC1(C)C)(C)C)=O BZPVRUBMPXSHSF-UHFFFAOYSA-N 0.000 claims 2
- KVIVXPHEVVIJKS-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-pyrimidin-2-yl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound N1=C(N=CC=C1)P1(OCC(NC1(C)C)(C)C)=O KVIVXPHEVVIJKS-UHFFFAOYSA-N 0.000 claims 2
- DAGQXYMRYJXTAJ-UHFFFAOYSA-N 3,3,5,5-tetramethyl-2-pyrimidin-5-yl-1,4,2lambda5-oxazaphosphinane 2-oxide Chemical compound N1=CN=CC(=C1)P1(OCC(NC1(C)C)(C)C)=O DAGQXYMRYJXTAJ-UHFFFAOYSA-N 0.000 claims 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
- 229960004640 memantine Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138 | 2020-05-20 | ||
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| PCT/FR2021/050929 WO2021234324A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531869A JP2023531869A (ja) | 2023-07-26 |
| JPWO2021234324A5 true JPWO2021234324A5 (https=) | 2024-05-27 |
| JP2023531869A5 JP2023531869A5 (https=) | 2024-05-27 |
Family
ID=73013493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571216A Pending JP2023531869A (ja) | 2020-05-20 | 2021-05-20 | 神経保護を誘導するための化合物及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4142703B8 (https=) |
| JP (1) | JP2023531869A (https=) |
| KR (1) | KR20230013116A (https=) |
| CN (1) | CN116981449A (https=) |
| CA (1) | CA3178633A1 (https=) |
| ES (1) | ES2970378T3 (https=) |
| FR (1) | FR3110393B1 (https=) |
| WO (1) | WO2021234324A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| WO2026003229A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament |
| FR3163835A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
| FR3163834A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100777904B1 (ko) * | 2002-10-24 | 2007-11-28 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료 |
| BRPI0516112A (pt) * | 2004-10-15 | 2008-08-26 | Janssen Pharmaceutica Nv | métodos para neuroproteção |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20120115943A1 (en) * | 2008-10-01 | 2012-05-10 | National Taiwan University | Composition and method for neuroprotection against excitotoxic injury |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| FR3006193B1 (fr) | 2013-05-29 | 2015-06-19 | Holis Technologies | Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda) |
| FR3050732B1 (fr) | 2016-05-02 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
-
2020
- 2020-05-20 FR FR2005138A patent/FR3110393B1/fr active Active
-
2021
- 2021-05-20 ES ES21734182T patent/ES2970378T3/es active Active
- 2021-05-20 KR KR1020227044712A patent/KR20230013116A/ko active Pending
- 2021-05-20 CN CN202180060125.1A patent/CN116981449A/zh active Pending
- 2021-05-20 CA CA3178633A patent/CA3178633A1/fr active Pending
- 2021-05-20 EP EP21734182.5A patent/EP4142703B8/fr active Active
- 2021-05-20 WO PCT/FR2021/050929 patent/WO2021234324A1/fr not_active Ceased
- 2021-05-20 JP JP2022571216A patent/JP2023531869A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2368604C2 (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| JP2006504656A5 (https=) | ||
| US20120225845A1 (en) | Compounds for diseases and disorders | |
| US9034871B2 (en) | Compounds for Alzheimer's disease | |
| RU98113786A (ru) | Новые соединения, обладающие анальгезирующим действием | |
| US20080188524A1 (en) | Methods of treating pain | |
| JP2003528095A5 (https=) | ||
| JP2005506308A5 (https=) | ||
| US20060079515A1 (en) | Method for the treatment of polycystic kidney disease | |
| EP1641461B1 (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| JP2005529926A5 (https=) | ||
| JP2002508364A5 (https=) | ||
| JP2022137234A (ja) | 神経変性疾患の予防及び／又は治療剤 | |
| JP6243265B2 (ja) | ロスバスタチン含有医薬製剤 | |
| JPWO2021234324A5 (https=) | ||
| JP7309824B2 (ja) | 不安障害を治療するための（２Ｓ）－１－［４－（３，４－ジクロロフェニル）ピペリジン－１－イル］－３－［２－（５－メチル－１，３，４－オキサジアゾール－２－イル）ベンゾ［ｂ］フラン－４－イルオキシ］プロパン－２－オールまたはその代謝産物 | |
| US20090155903A1 (en) | Pharmaceutical composition and method | |
| JP5386478B2 (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| EA003255B1 (ru) | Комбинация производных тетрагидропиридинов и ингибиторов ацетилхолинэстеразы для лечения старческой деменции по типу альцгеймера | |
| JP6025886B2 (ja) | 慢性疼痛治療剤 | |
| KR930006009A (ko) | 4-[4-[4-(4-히드록시페닐)-1-피페라지닐]페닐]-5-메틸-3h-1,2,4-트리아졸-3-온 유도체 | |
| CN102796121A (zh) | 3-芳基-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类衍生物及其应用 | |
| JPH11335286A (ja) | ドーパミン拮抗薬の効果増強剤 | |
| TW201208683A (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |